NCT06492538 Biometric Changes After Intervention of Anterior Chamber Angle : an Observational Study
| NCT ID | NCT06492538 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhongshan Ophthalmic Center, Sun Yat-sen University |
| Condition | Angle-closure Glaucoma |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2023-12-01 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2023-12-01 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The drainage angle in the anterior chamber of the eye mediates the outflow of aqueous humor, and pathological changes here can lead to high intraocular pressure and glaucoma. Minimally invasive glaucoma surgery, particularly angle surgery, has advanced recently, allowing clear visualization of angle structures like the trabecular meshwork and Schlemm's canal using surgical goniolens. Techniques for angle intervention include widening the angle, reopening closed angles, and rebuilding outflow pathways using methods such as laser peripheral iridotomy, Argon laser peripheral iridoplasty, and mechanical separation of adhered tissues. Our research team plans to conduct imaging studies to track the healing of angle tissues post-surgery, aiming to support innovation and standardization of minimally invasive angle surgery.
Eligibility Criteria
Inclusion Criteria: * Glaucoma patients eligible for standalone or combined angle intervention surgeries, such as LPI, LPIP, goniosynechialysis, trabeculotomy alone or combined with surgical iridectomy or phacoemulsification and intraocular lens implantation; * Patients capable of undergoing preoperative examinations including CASIA2-OCT (anterior segment OCT), UBM, slit-lamp gonioscopy, IOL Master (or other optical biometry); * Patients willing to participate in this study, signing informed consent, and agreeing to follow-up according to the study protocol. Exclusion Criteria: * Patients with severe ocular conditions such as corneal infection, ulcer, trauma, ocular tumors, retinal vascular occlusion, and retinal detachment; * Those with various types of eye diseases that affect ocular parameter acquisition or interfere with visual field examination; * Long-term local or systemic use of glucocorticoids; * Patients with severe systemic diseases; * Pregnant or lactating women; * Unable to complete 12-month postoperative follow-up.
Contact & Investigator
Xinbo Gao, MD
PRINCIPAL INVESTIGATOR
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University
Frequently Asked Questions
Who can join the NCT06492538 clinical trial?
This trial is open to participants of all sexes, aged 30 Years or older, up to 85 Years, studying Angle-closure Glaucoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06492538 currently recruiting?
Yes, NCT06492538 is actively recruiting participants. Contact the research team at gaoxb@mail.sysu.edu.cn for enrollment information.
Where is the NCT06492538 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06492538 clinical trial?
NCT06492538 is sponsored by Zhongshan Ophthalmic Center, Sun Yat-sen University. The principal investigator is Xinbo Gao, MD at State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University. The trial plans to enroll 300 participants.